The menopause and hormone replacement therapy: Lipids, lipoproteins, coagulation and fibrinolytic factors

Maturitas

Volumn 23, Issue 2, 1996, Pages 209-216

  Tikkanen, Matti J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Hemostatic system; Hormone replacement therapy; Menopause; Plasma lipoprotein

Indexed keywords

ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN;

ADULT; ANTIOXIDANT ACTIVITY; BLOOD CLOTTING; CONFERENCE PAPER; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LIPOPROTEIN METABOLISM; MENOPAUSE; RISK FACTOR; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0029892778     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(95)00950-7     Document Type: Conference Paper

References (66)

1. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991; 265: 1861-1867.
2. Hallberg L, Svanborg A. Cholesterol, phospholipids, and triglycerides in plasma in 50 year-old women. Influence of menopause, body-weight, skinfold thickness, weight-gain, and diet in a random population sample. Acta Med Scand 1967; 181: 185-194.
3. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976; 85: 447-452.
4. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. New Engl J Med 1989; 321: 641-646.
5. Farish E, Fletcher CD, Hart DM, Smith ML. Effects of bilateral oophorectomy on lipoprotein metabolism. Br J Obstetr Gynaecol 1991; 97: 78-82.
6. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-331.
7. Campos H, McNamara JR, Wilson PWF, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metabol 1988; 167: 30-35.
8. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy menopausal women. Metabolism 1993; 42: 1153-1158.
9. van der Mooren MJ, de Graaf J, Demacker PN, De Haan AF, Rolland R. Changes in the low-density lipoprotein profile during beta-estradiol-dydrogesterone therapy in posmenopausal women. Metabolism 1994; 43(7): 799-802.
10. deGraaf J, Hak-Lemmers HL, Hectors MC, Demacker PN, Hendricks JC, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscleros Thrombos 1971; 11: 298-306.
11. Sack MN, Rader DJ, Cannon, RO III. Oestrogen and inhibition of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269-270.
12. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell DR, ed. Menopause: physiology and pharmacology. Chicago: Year Book Medical Publishers 1987; 187-208.
13. Lobo RA. Clinical review 27. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metabol 1991; 73: 925-930.
14. Fåhraeus L. The effects of estradiol on blood lipids and lipoproteins in postmenopausal women. Obstetr Gynecol 1988; 72: 18S-22S.
15. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New Engl J Med 1991; 325: 1196-1204.
16. PEPI writing group. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women. J Am Med Assoc 1995; 3: 199-208.
17. Tikkanen MJ, Nikkilä EA, Vartiainen E. Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women. Lancet 1978; 490-492.
18. Moorjani S, Dupont A, Labrie F, De Lignières B, Cusan L, Dupont P, Mailloux J, Lupien P-J. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestran in menopausal women. J Clin Endocrinol Metabol 1991; 73: 373-379.
19. Eisenberg S, Deckelbaum R. Intravascular lipoprotein remodelling: neutral lipid transfer proteins. In: Fruchart JC, Shepherd J, eds. Human Plasma Lipoproteins. Berlin; Walter de Gruyter and Co., 1989; 153-161.
20. Tikkanen MJ. Combination of estradiol-valerate and cyproterone acetate - a modern regimen for hormone replacement therapy. New Dev Biosci 1992; 7: 9-15.
21. Tikkanen MJ, Nikkilä EA, Kuusi T, Sipinen S. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metabol 1982; 54: 1113-1117.
22. Schaefer EJ, Zech LA, Jenkins LL, Bronzert TL, Rubalcaba EA, Lindgren FT, Amodt RL, Brewer HB. Human Apoliprotein A I and A II metabolism. J Lipid Res 1982; 23: 850-862.
23. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 1994; 35: 2083-2093.
24. Tikkanen MJ, Kuusi T, Nikkilä EA, Sipinen S. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins. A review. Maturitas 1986; 8: 7-17.
25. Krauss RM. Effects of progestational agents on serum lipids and lipoproteins. J Reprod Med 1982; 27: 503-510.
26. Hirvonen E, Mälkönen M, Manninen V. Effect of different progestogens on lipoproteins during postmenopausal replacement therapy. New Engl J Med 1981; 304: 560-563.
27. Rijpkema AHM, van den Sanden AA, Ruijs AHC. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12: 259-285.
28. Newnham HH. Oestrogens and atherosclerotic vascular disease - lipid factors. In: Burger HG, ed. Baillière's Clinical Endocrinology and Metabolism: The Menopause. London: Baillière Tindall, 1993; 7: 61-93
29. Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstetr Gynecol 1987; 156: 66-71.
30. Mattsson L-Å, Samsioe G, von Schoulz B, Uvebrandt M, Wiklund I. Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women. Br J Obstetr Gynaecol 1993; 100: 450-453.
31. Lindgren R, Berg G, Hammar M, Larsson-Cohn U, Olsson AG. Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate. Eur J Obstetr Gynecol Reprod Biol 1992; 47: 213-221.
32. International Task Force for the Prevention of Coronary Heart Disease. Prevention of coronary heart disease: Scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1982; 2: 113-156.
33. Zysow BR, Lawn RM. The relationship of lipoprotein (a) to hemostasis. Curr Opin Lipidol 1993; 4: 484-489.
34. Meilahn EN, Kuller LH, Matthews KA, Stein A. Lp(a) concentrations among pre-and postmenopausal women over time: the Healthy Women Study. Circulation 1991; 84 (suppl II): 546.
35. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein (a) to variables to coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37: 1950-1954.
36. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chesnut CH, Hazzard WR. Reduction of lecithincholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta 1984; 795: 293-296.
37. Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. Br Med J 1991; 303: 694.
38. Crook D, Sidhu M, Seed M, Stevenson JC. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992; 92: 41-47.
39. Rymer J, Crook D, Sidhu M, Chapman M, Stevenson JC. Effects of tibolone on serum concentrations of lipoprotein (a) in postmenopausal women. Acta Endocrinol (Copenhagen) 1993; 128: 259-262.
40. Soma M, Osnago-Gadda I, Paoletti R, Fumagalli R, Morrisett JD, Meschia M, Crosignani P. The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993; 153: 1462-1468.
41. van der Mooren MJ, Demacker PNM, Thomas CMG, Rolland R. Beneficial effect on serum lipoprotein by 17-oestradiol-dydrogesterone therapy in postmenopausal women: a prospective study. Eur J Obstetr Gynecol Reprod Biol 1982; 47: 153-160.
42. Marsh MS, Crook D, Ellerington MC, Whitcroft SI, Whitehead MI, Stevenson JC. Effect of continuous combined estrogen replacement therapy on serum lipids and lipoproteins. Obstetrics and Gynecology (in press).
43. Kim CJ, Jang Hc, Cho DH, Min YK. Effects of Hormone Replacement Therapy on Lipoprotein(a) and Lipids in Postmenopausal Women. Arterioscler Thromb 1994; 14: 275-281.
44. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. J Clin Invest 1992; 89: 1166-1171.
45. Bhatnagar D, Durrington PN. Does measurement of apolipoproteins add to the clinical diagnosis and management of the dyslipidemias. Curr Opin Lipidol 1993; 4: 299-304.
46. Vessey MP. Female hormones and vascular disease: an epidemiologic overview. Br J Fam Plan 1980; 6 (Suppl): 1-12.
47. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemol Rev 1985; 7: 80-104.
48. Barrett-Connor E, Bush TL. Estrogen replacement and coronary heart disease. In: Douglas PS, ed. Cardiovascular Clinics: Heart Disease in Women. Philadelphia: F.A. Davis Company, 1989, pp. 159-172.
49. Lufkin EG, Ory SJ. Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo Clin Proc 1994; 69: 131-135.
50. Coope J, Thomson JM, Poller L. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975; 4: 139-143.
51. Bonnar J, Haddon M, Hunter DH, Richards DH, Thornton C. Coagulation system changes in postmenopausal women receiving oestrogen preparations. Postgrad Med J 1976; 52 (Suppl): 30-36.
52. Poller L, Thomson JM, Coope J. Conjugated equine oestrogens and blood clotting: a follow-up report. Br Med J 1977; 1: 935-936.
53. Robinson RW, Lebeau RJ. Effect of conjugated equine estrogens on serum lipids and the clotting mechanism. J Atheroscleros Res 1965; 5: 120-124.
54. Beller FK, Nachtigall L, Rosenberg M. Coagulation studies of menopausal studies of menopausal women taking estrogen replacement. Obstetr Gynecol 1972; 39: 775-778.
55. Notelovitz M, Greig HB. The effect of natural oestrogens on coagulation. South Afr Med J 1975; 49: 101-105.
56. Davies T, Fieldhouse G, McNicol GP. The effects of therapy with oestriol succinate and ethinyl oestradiol on the haemostatic mechanism in post-manopausal women. Thrombos Haemostas 1976; 35: 403-414.
57. Sporrong T, Mattsson LA, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstetr Gynaecol 1990; 97: 939-944.
58. Caine YG, Bauer Ka, Barzeger S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thrombosis-Haemostasis 1992; 68(4): 392-395.
59. Judd HL, Meldrum DR, Deftos LJ, Henderson BE. Estrogen replacement therapy: indications and complications. Ann Intern Med 1983; 98: 195-205.
60. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. New Engl J Med 1993; 15: 1069-1075
61. Hamsten A. Coagulation factors and hyperlipidaemia. Curr Opin Lipidol 1991; 2: 266-271.
62. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biologic effects of transdermal estradiol. New Engl J Med 1986; 314: 1615-1620.
63. Alkjaersig N, Fletcher AP, de Ziegler D, Steingold KA, Meldrum DR, Judd Hl. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. J Lab Clin Med 1980; 111: 224-228.
64. Fox J, George AJ, Newton JR, Parsons AD, Stuart GK, Stuart J, Sturdee DW. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993; 18: 55-64.
65. Miller-Bass K, Adashi EY. Current status and future prospects of transdermal estrogen replacement therapy. Fertil Steril 1990; 53: 961-974.
66. Tikkanen MJ. Mechanisms of cardiovascular protection by postmenopausal hormone replacement therapy. Cardiovasc Risk Factors 1993; 3: 138-143.